Kimberley Warren welcomed as SVP Business Development, Human Health

Warren joins GreenLight from Epizyme Inc. and previously Sanofi, where she was responsible for the negotiation of in-licensing, out-licensing, co-development, and research collaboration agreements. Warren’s background includes over 20 years of  business development experience, a PhD in Medicinal Chemistry and MBA.  Warren has specific experience in the negotiation of collaborations for the development of mRNA therapies. 

“GreenLight aims to address humanity’s greatest challenges, from producing vaccines to protecting bees,” said Marta Ortega-Valle, co-founder and CBO of GreenLight Biosciences.  “Kim’s experience at negotiating complex bio-pharmaceutical partnerships across vaccines and oncology will be a huge asset as we seek strategic collaborations with pharmaceutical and biotechnology companies.”

“RNA technology has been validated in the last year by COVID vaccines. I am excited to join GreenLight, where we plan to expand our collaborations on vaccines and oncology,” Warren said. “Our platform is an exciting opportunity to solve some of the world’s greatest challenges.”

Warren will report to co-founder Marta Ortega-Valle and lead efforts to expand GreenLight’s partnerships.

Founded in 2008, GreenLight has raised $230 million to date and is rapidly expanding to new market opportunities in human health, animal health, and plant health. Last year, GreenLight raised more than $100 million in an oversubscribed series D round to accelerate efforts around a COVID-19 vaccine and messenger RNA manufacturing.

Key investors include Morningside, Baird Capital, Cormorant Asset Management, Fall Line, S2G Ventures, Lupa Systems Capital, Continental Grain Company, and Prelude Ventures.